VolitionRX Ltd VNRX
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2015-02-06 |
| Shares Out. | 11,590,000 |
| Website | volition.com/ ↗ |
| Phone | 13025750877 |
| Employees | 75 |
| Revenue | $985,076 |
| Gross Profit | $985,076 |
| Net Income | -$6.7M |
| Free Cash Flow | -$20.8M |
| Total Assets | $9.0M |
| Total Liabilities | $42.4M |
| Equity | -$33.4M |
About VolitionRX Ltd
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
VolitionRX Ltd is a publicly traded company under the ticker symbol VNRX on the NYSE MKT LLC, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)